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Liver transplantation has become a lifesaving proce-
dure for patients who have chronic end-stage liver 
disease and acute liver failure. The satisfactory out-
come of liver transplantation has led to insufficient 
supplies of deceased donor organs, particularly in 
East Asia. Hence, East Asian surgeons are concen-
trating on developing and performing living-donor liver 
transplantation (LDLT). This review article describes 
an update on the present status of liver transplan-
tation, mainly in adults, and highlights some recent 
developments on indications for transplantation, patient 
selection, donor and recipient operation between LDLT 
and deceased-donor liver transplantation (DDLT), im-
munosuppression, and long-term management of liver 
transplant recipients. Currently, the same indication 
criteria that exist for DDLT are applied to LDLT, with 
technical refinements for LDLT. In highly experienced 
centers, LDLT for high-scoring (＞30 points) Model of 
End-Stage Liver Disease (MELD) patients and acute- 
on-chronic liver-failure patients yields comparably good 
outcomes to DDLT, because timely liver transplan-
tation with good-quality grafting is possible. With in-
creasing numbers of liver transplantations and long- 
term survivors, specialized attention should be paid to 
complications that develop in the long term, such as 
chronic renal failure, hypertension, diabetes mellitus, 
dyslipidemia, obesity, bone or neurological complica-
tions, and development of de novo tumors, which are 
highly related to the immunosuppressive treatment. 
(Gut and Liver 2009;3:145-165)
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INTRODUCTION - HISTORICAL PERSPECTIVES
  Today, liver transplantation is a lifesaving procedure for 
patients with chronic end-stage liver disease and acute 
liver failure (ALF) when there are no available medical 
and surgical treatment options.
1-3 Thomas Starzl per-
formed the first three human liver transplantation at the 
University of Colorado in 1963, but did not achieve 
1-year survival until 1967. Over the next 15 years, rela-
tively few liver transplantation were performed, and the 
1-year survival rate was only 30% until the late 1970s 
and early 1980s when the implementation of cyclo-
sporine-based immunosuppression led to doubling of the 
1-year survival rate.
1 In 1983, these improved outcomes 
led to the decision at a National Institutes of Health 
Consensus Development Conference that liver transplan-
tation was no longer experimental procedure and de-
served broader application in clinical practice.
4 This meet-
ing initiated the modern era of liver transplantation and 
resulted in the propagation of liver transplantation across 
the United States and around the world. 
  Since the early 1980s, there have been significant ad-
vances in all aspects of liver transplantation, including re-
cipient selection, donor management, operation technique, 
immunosuppression, and postoperative management of 
liver recipients. These changes, which have marked the 
evolution from an experimental technique to established 
and routine therapy, have resulted in enormous improve-
ments in outcome. The overall 1-year survival for adult 
and pediatric deceased donor liver transplantation (DDLT) 
i s  n o w  e x p e c t e d  t o  b e  i n  e x c e s s  o f  8 5 % ,  w i t h  5 -  a n d  
10-year survival in excess of 70% and 60%, respec-
tively.
5-8146   Gut and Liver, Vol. 3, No. 3, September 2009
Fig. 1. Number of deceased donor livers available in various 
countries in 2000. Reprinted from de Villa VH, Lo CM, Chen 
CL. Ethics and rationale of living-donor liver transplantation in 
Asia. Transplantation 2003;75(3 Suppl):S2-S5.
Fig. 2. A n n u a l  n u m b e r  o f  l i v e r  
transplantations performed at 
the Asan Medical Center, Ulsan 
University College of Medicine. 
The reduction in the accepted 
remnant liver volume from ＞
35% to ＞30% of the donor’s
total liver volume in 2005 
resulted in a decrease in the 
proportion of dual-graft LDLTs. 
In 2008 there was a marked 
increase in organ donations, 
which was fueled by organ 
donation from a famous boxer 
in early 2008, hence reducing 
the number of LDLTs. 
LDLT, living donor liver trans-
plantation; DDLT, deceased do-
nor liver transplantation.
  The success of liver transplantation as treatment for 
most types of acute and chronic liver failure has led to 
increased referrals for transplantation in the setting of a 
relatively fixed supply of cadaveric donor organs.
1 At the 
end of 2006, more than 17,000 patients were listed for 
liver transplantation in the United States.
9 Despite per-
formance of more than 6,000 liver transplantations annu-
ally in the United States during the past several years,
9,10 
only one thirds of candidates received liver transplanta-
tion and almost 2,000 deaths have occurred annually in 
patients listed for liver transplantation during past 6 
years.
1 The persistent shortage of donor organs is ob-
viously insufficient to meet the growing demand for liver 
tran splantation . This kind of im balan ce betw een the sup-
ply of donor organ and the patients’ numbers demanding 
liver transplantation is extremely severe in the region of 
East Asia including Korea, Japan, Hong Kong and Taiwan 
(Fig. 1). The disparity between supply and demand might 
be related to inadequate understanding for organ dona-
tion after brain death mainly influenced by Confucianism 
and also insufficient legal supporting system. Although 
the first successful living donor liver transplantation 
(LDLT) was performed for pediatric recipient using lateral 
sector (Couinaud’s segment 2 and 3) by Strong RW in 
1989, the above situation in the East Asia led surgeons 
having hum anistic enthusiasm  to concentrate on develop-
ing and performing LDLT as an alternative.
  The first successful liver transplantation in Korea was 
performed using deceased donor whole-size liver by Kim 
ST in 1988.
11 In the early 1990s, liver transplantation was 
slowly developed as a feasible option in the treatment of 
end-stage liver disease in Korea mainly because of the se-
vere shortage of deceased donor liver grafts. In 1994, Lee 
SG performed the first successful pediatric LDLT in 
6-month old female biliary atresia child with her father’s 
left lateral sector.
12
  The success in pediatric liver transplantation and the 
shortage of organs provided the necessary incentive to at-
tempt living donations for adult recipients.
13 The accumu-
lated knowledge of the sophisticated hepatobiliary surgery 
as well as the experiences of DDLT and pediatric LDLT  
finally made us to perform the first successful adult LDLT 
using left lobe in 1997 February.
14 The emerging aware-
ness of the importance of graft volume and low graft-to- Moon DB, et al: Liver Transplantation   147
Fig. 3. Comparison of indications for liver transplantation between Korea and the United States. 
HBV, hepatitis B virus; LC, liver cirrhosis; HCC, hepatocellular carcinoma; FHF, fulminant hepatic failure; HCV, hepatitis C virus;
SBC, secondary biliary cirrhosis; PBC, primary biliary cirrhosis; AIH, autoimmune hepatitis; CCC, cholangiocarcinoma; Re-LT, 
retransplantation; PSC, primary sclerosing cholangitis; BD, bile duct.
recipient weight ratio led us to initiate right lobe LDLT 
in adults from 1997 July.
13 On the contrary to Hong Kong 
Group,
15 we designed modified right lobe graft to reduce 
the risk to the donor after right lobe donation by leaving 
middle hepatic vein to the donor’s remaining liver, and 
reconstruction of divided but sizable-middle hepatic vein 
branches to prevent congestion of anterior sector in the 
recipient’s side.
16,17 T h i s  i n n o v a t i v e  d e s i g n  o f  r i g h t  l o b e  
graft has contributed to rapid expansion of our adult liv-
ing donor liver transplantation program (Fig. 2). In addi-
tion, in order to alleviate the small for size graft problem 
to the recipients and donor risk from harvesting right 
lobe from suboptimal donor simultaneously, dual-grafts 
LDLT was initiated in 2000 March.
18 Thereafter, the do-
nor rejection rate due to inadequate volume or excessive 
steatosis was reduced from 40% to 20%.
19
  T h e  a i m  o f  t h i s  r e v i e w  i s  t o  g i v e  a n  u p d a t e  o n  t h e  
present status of liver transplantation mainly in adults, 
and to highlight some recent developments on indications 
for transplantation, patient selection, perioperative care, 
immunosuppression, and long-term management of liver 
transplant recipients. 
INDICATIONS AND CONTRAINDICATIONS
  Cirrhosis accounts for more than 80% of transplants 
performed in adults, and the most important indications 
for liver transplantation in the United States are hepatitis 
C (21%), alcoholic liver disease (16%), cholestatic liver 
disease including primary biliary cirrhosis and sclerosing 
cholangitis (17%). Other indications are chronic hepatitis 
(hepatitis B, autoimmune hepatitis), metabolic disease 
(Wilson’s disease, nonalcoholic steatohepatitis), fulminant 
hepatic failure, and non-metastatic hepatocellular carcino-
ma (HCC).
20 However, the most common indications of 
liver transplantation in Korea are hepatitis B (81%) in-
cluding HCC (21.5%) and then fulminant hepatic failure 
(7%), alcoholic liver disease (4%) and hepatitis C (3%). 
Recently the proportion of hepatitis C and alcoholic liver 
disease is slowly increasing and the indications of liver 
transplantation become resembling to Western countries 
year by year (Fig. 3).
21 Major pediatric indications for liv-
er transplantation include biliary atresia and metabolic 
diseases.
   Patients with hepatitis B cirrhosis and high viremia 
were not eligible for transplantation in the past because 
of the high risk of recurrence after transplantation with 
consequent rapid graft loss. Since the availability of anti-
viral medication, high viremia is treatable and trans-
plantation has become a more realistic option with ex-
cellent graft and patient survival that is even superior to 
that of many other indications.
22 After transplantation, 
antiviral treatment, often including hepatitis B immune 
globulin, is continued to prevent recurrent infection.
23
  HCC is a well-recognized indication for transplantation 
when the patients have Child B and C liver cirrhosis at 148   Gut and Liver, Vol. 3, No. 3, September 2009
the same time. Generally, only patients who meet the 
Milan criteria of a single tumor up to 5 cm or up to three 
tumors with less than 3 cm and no major vascular in-
vasion such as portal and hepatic vein, as determined by 
imaging studies,
24 are approved by the transplant organ-
izations in most countries. Survival rates for these pa-
tients are comparable to those for cirrhosis leading to 
transplant without a complicating HCC recurrence. Preo-
perative base-line metastatic work-up includes bone scan 
and chest computed tomography (CT). Recently, positron 
emission tomography (PET) scan also tends to be in-
cluded because of the usefulness to find undetected ma-
lignancy and to avoid legal issue. Discussion at present 
focuses on expansion of these strict criteria, as on the 
one hand the removed liver often shows more tumor le-
sions than expected, and on the other hand patients with 
somewhat larger lesions often do well.
25 Yao et al. have 
shown that patients who have single tumor 6.5 cm in di-
ameter or smaller or three or fewer tumors with largest 
being 4.5 cm or less in diameter and a total tumor bur-
den of 8.0 cm or less (the so-called “UCSF criteria”) ach-
ieved results that were not different from those of pa-
tients belonging to Milan criteria.
26 Lee et al. proposed 
Asan Medical Center (AMC) criteria from the results of 
LDLT for HCC, based on explant pathology, that were 
largest tumor diameter ≤5 cm, number ≤6, and no gross 
vascular invasion. It had similar prognostic power but 
highest discriminatory power than Milan and UCSF cri-
teria.
27 Finally, radiofrequency ablation and chemoemboli-
zation have become bridging therapies to transplantation 
while patient is waiting on the liver transplant list.
28,29
  Chronic hepatitis C virus (HCV) infection is the lead-
ing indication for liver transplantation in United States, 
and the number of transplantation for this indication is 
expected to increase dramatically over the next 10 to 20 
years.
30,31 Retransplantation for patients who develop al-
lograft dysfunction as a result of recurrent hepatitis C re-
mains controversial, because outcomes are often poor,
32 
and antiviral therapy of recurrent HCV infection has rela-
tively low efficacy.
33
  For alcoholic liver disease, the prerequisites for trans-
plantation in most centers are alcohol abstinence for at 
least six months and active treatment for alcohol depend-
ency before transplantation.
34,35
  ALF, also called “fulminant hepatic failure,” and the 
more indolent variant, subfulminant hepatic failure, are 
characterized by the development of liver failure man-
ifested by coagulopathy, jaundice, and encephalopathy 
leading to coma in the absence of chronic liver disease.
36 
ALF accounts for 5% to 6% of all liver transplantations.
9 
Acetaminophen hepatotoxicity is the leading cause of 
ALF, whereas idiosyncratic drug-induced liver injury is 
the major cause of subfulminant hepatic failure.
36 Patients 
who have ALF can recover spontaneously, but those with 
subfulminant hepatic failure are expected to have 100% 
mortality without transplantation.
10,36 Transplantation in-
dications ALF are usually based on King’s College cri-
teria,
37 and/or Clichy criteria.
38 However, it is often rec-
ommended that patients with ALF who fail to meet 
King’s College criteria still be considered for liver trans-
plantation, because spontaneous recovery is not guaran-
teed.
1 Timely referral and liver transplantation is of para-
mount importance, because death from sepsis and cere-
bral edema may occur within days of onset of stage 3 or 
4 hepatic encephalopathy.
2,10,36 Lee et al.
39 described that 
the timely LDLT using appropriate graft type sufficing at 
least more than 40% of patient’s standard liver volume 
with minimal steatosis resulted in remarkably improved 
survival rate for adult ALF patients in this region where 
deceased organ donation is very scarce.
  Graft failure with the need for retransplantation ac-
counts for an increasing number of transplantations. Sho-
rtly after transplantation, this mainly concerns primary 
nonfunction of liver grafts and hepatic artery thrombosis, 
later biliary complications and recurrent hepatitis C can 
become indications for retransplantation.
25
  In general, the past few years are characterized by an 
increasingly shorter list of absolute contraindications and 
a growing list of indications for liver transplantation. 
Specific type of Budd-Chiari syndrome and severe portal 
vein thrombosis and/or stenosis, previously considered as 
a anatomic abnormality precluding liver transplantation, 
were no longer contraindication for liver transplantation. 
For Budd-Chiari syndrome, thrombosis and/or stenosis 
extending to intrapericardial inferior vena cava (IVC) and 
almost orifice of right atrium, Lee et al. replaced the dis-
eased stenotic retrohepatic vena cava of the recipient with 
a large caliber Dacron interposition graft between right 
atrium and infraheaptic IVC (Fig. 4).
13 Portal venous 
thrombosis, sclerosis and size discrepancy between the 
graft and recipient’s portal vein (PV) are other issues that 
make it difficult or impossible to perform standard end- 
to-end anastomosis. These problems are usually overcome 
by the use of PV thrombectomy and venoplasty, and addi-
tionally portal vein stenting by using intraoperative porto-
gram if necessary (Fig. 5).
40 Sometimes interposition vas-
cular graft from superior mesenteric vein or left renal 
vein when large splenorenal shunt is accompanied, should 
be used to supply mesenteric blood to the graft, which is 
essential for graft regeneration (Fig. 6).
41,42
  Most generally accepted absolute contraindications to 
transplantation are noted in Table 1. Transplant centers Moon DB, et al: Liver Transplantation   149
Fig. 4. LDLT with replacement of the inferior vena cava using a Dacron interposition graft for Budd-Chiari syndrome. (A) 
Preoperative CT scan showing typical findings of Budd-Chiari syndrome: retrohepatic obliteration of the inferior vena cava (multiple 
arrows), and portal vein stenosis and a large coronary collateral vein (black and white arrowheads, respectively). (B) Intraoperative
photograph showing replacement of the inferior vena cava with a Dacron interposition graft between the right atrium and the 
suprarenal inferior vena cava (white arrowhead), and middle hepatic vein tributaries reconstructed using cryopreserved cadaveric iliac
vein grafts. (C) Two-year postoperative CT scan revealing a patent replaced inferior vena cava, right hepatic vein, and portal vein 
without stenosis (white arrowhead, white arrow, and black arrowhead, respectively). 
LDLT, living donor liver transplantation.
Fig. 5. Portal vein plasty with 
the great saphenous vein and 
intraoperative stent placement 
for severe portal vein stenosis. 
(A) Preoperative CT scan sho-
wing severe portal vein stenosis 
and abundant ascites. (B) The 
liver graft regenerated well and 
ascites had disappeared by the 
2-month postoperative follow- 
up, as revealed by this C T scan, 
after intraoperative portal vein 
plasty with an autogenous great 
saphenous vein (GSV, indicated 
by the separate figure in the 
small box) and additional stent 
placement (black arrow).150   Gut and Liver, Vol. 3, No. 3, September 2009
Fig. 6. Renoportal anastomosis using a cadaveric fresh iliac vein graft for an obliterated portal vein, and large spontaneous 
splenorenal shunts. (A) Preoperative CT scan showing obliterated portal vein stenosis and large spontaneous splenorenal shunts 
draining most of the splanchnic blood flow into the left renal vein (LRV, black arrow). (B) Intraoperative photography showing an 
interposition cadaveric fresh iliac vein graft (IPG) anastomosed to the left renal vein. The black arrow indicates the interruption 
suture running between the inferior vena cava (IVC) and the left renal vein in order to prevent portal flow stealing. (C) Patent 
interposition iliac vein graft between the left renal vein and the grafted portal vein. A well-regenerated liver is visible on the 2-year
postoperative follow-up CT scan.
Table 1. Contraindications to Liver Transplantation
  Anatomic abnormality precluding liver transplantation
  Malignancy outside the liver
  U n t r e a t e d  s e p s i s
  Advanced cardiopulmonary disease
  Active alcohol and drug use
  A I D S
Table 2. Model for End-Stage Liver Disease Score
MELD score
Three-month mortality
(Hospitalized patients)
≤94 %
10-19 27%
20-29 76%
30-39 83%
≥40 100%
MELD score=9.57×loge  (Creatinine mg/dl)+3.78×
loge  (Bilirubin mg/dl)+11.20×loge  (INR)+6.43
Reprinted from Kamath PS, Wiesner RH, Malinchoc M, et al. 
A model to predict survival in patients with end-stage liver 
disease. Hepatology 2001;33:464-470.
are now increasingly offering liver transplantation to care-
fully selected older patients and human immune-defici-
ency virus (HIV)-infected individuals in the absence of ac-
quired immune deficiency syndrome (AIDS).
43
LISTING AND TIMING OF LIVER TRANSPLAN-
TATION
  The presence of cirrhosis alone is not sufficient to war-
rant transplantation. Although the high level of morbidity 
and mortality in chronic liver disease is related to compli-
cations of cirrhosis, the well-compensated cirrhotic pa-
tient can remain stable for many years. Fattovich et al.
44 
reported a 91% 5-year survival rate in a cohort of 384 cir-
rhotic HCV patients. However, once an index manifes-
tation of decompensation had occurred such as variceal 
bleeding, ascites, spontaneous bacterial peritonitis, hep-
atorenal syndrome, and occurrence of HCC, etc., survival 
dropped to 50% at 5 years, suggesting that referral for 
liver transplantation should be considered once an index 
complication has occurred.
  Since the application of the Model of End-Stage Liver 
Disease (MELD) score for organ allocation in 2002 by the 
Unite Network for Organ Sharing (UNOS), cirrhotic pa-
tient has to meet minimal listing criteria for placement 
on the deceased donor waiting list (Child-Turcotte-Pugh 
score of at least 7 for most causes of cirrhosis). Once ap-
proved for listing, the patients is prioritized according to 
the MELD score.
45 This score, based on objective labo-
ratory values, predicts the 3-month mortality of patients 
awaiting liver transplantation. The MELD score incorpo-
rates serum creatinine, bilirubin, and prothrombin time 
(INR). The formula for the MELD score and 3-month 
mortality is available on the Internet at www.mayoclinic. Moon DB, et al: Liver Transplantation   151
Fig. 7. CT scan showing changes 
between before and after liver 
transplantation. (A) HBV-related 
acute-on-chronic liver failure pa-
tient with huge ascites, altered 
mentality, and high MELD score 
(40 points). (B) Good regenera-
tion of dual liver grafts is visible 
and the ascites have disappeared 
on this 1-month postoperative 
follow-up CT scan.
org/meld/mayomodel6.html (Table 2).
46 The driving force 
of this system is disease severity, and there is no inherent 
benefit to early listing. In fact, listing too early may waste 
time and resources and cause the patient anxiety. A 
MELD score 10 or any complication of portal hyperten-
sion is an appropriate indication for transplant evalua-
tion.
43
  If cirrhotic patients have more than MELD score of 30, 
3-month survival will be less than 20%, so-called “acute- 
on-chronic liver failure (ACLF), UNOS 2A” state. The pa-
tients show similar clinical findings to ALF, but manifest 
underlying liver cirrhosis and related portal hypertension. 
Treatment strategies are timely liver transplantation using 
good quality graft including deceased donor whole liver or 
living donor partial liver graft having more than 50% of 
recipient’s standard liver volume and minimal fatty cha-
nge. At our institution, 16% of the adult LDLT was ur-
gently performed for ACLF patients and the 1-year and 
5-year survival rates were 84% and 79% respectively. 
These successful results indicate that ACLF patients are 
one of the most appropriate candidates for adult LDLT 
(Fig. 7).
47
RECIPIENT OPERATIONS
1. Deceased donor whole liver transplantation
45
  The recipient operation consists of total hepatectomy of 
the native liver followed by implantation of the donor 
liver. The native hepatectomy usually begins with division 
of the ligamentous attachment of the liver, followed by 
skeletonization of the hilar structures (bile duct, hepatic 
artery, and portal vein) to prepare for implantation of the 
new liver. The IVC is encircled above and below the liver 
to achieve full vascular control. Committing the patient to 
transplant, diseased liver is removed with retrohepatic 
IVC. The donor liver is surgically prepared for im-
plantation on the back table, then brought onto the oper-
ative field. Anastomoses are constructed between the do-
nor liver and recipient in the following sequence: supra-
hepatic IVC, infrahepatic IVC, and PV anastomosis. Once 
the PV is anastomosed, the clamp is removed in sequence 
and the liver is perfused in PV inflow. 
  The hepatic artery is typically connected to the recipi-
ent hepatic artery with large luminal diameter at the 
junction of the gastroduodenal artery. Thereafter, bile 
duct is reconstructed using an end-to-end choledocho-
choledochostomy. If the recipient bile duct is not appro-
priate for end-to-end reconstruction, a Roux-en-Y chol-
edochojejunostomy is performed.
2. Living donor liver transplantation
  The surgical technique for recipients is based on whole 
liver resection, with preservation of the IVC removed for 
whole DDLT.
48 However, it is more sophisticated oper-
ation and needs much more careful and delicate dis-
section than DDLT, because living donor partial liver 
graft having much smaller-sized hepatic artery, vein and 
PV should be implanted. For technically successful oper-
ation, it is important to make a large and long opening 
along the sides of the hepatic veins and important to 
maintain satisfactory portal, biliary and hepatic arterial 
sources for the reconstruction (Fig. 8).
49 Anastomosis is 
performed in the following order: hepatic vein, PV and 
then hepatic artery. The provision of adequate outflow is 
indispensable for graft function; thus, it is necessary to 
obtain a wide orifice and an enough length of the hepatic 
vein for anastomosis.
50 Hepatic arterial reconstruction is 
technically difficult due to the existence of short, thin and 
small hepatic arteries on the liver graft, particularly in the 
East Asian people. The Kyoto group introduced micro-
vascular surgery and report excellent outcomes.
51 It be-
comes standard technique for hepatic anastomosis cur-152   Gut and Liver, Vol. 3, No. 3, September 2009
Fig. 8. Interrelationship betw-
een graft volume, hepatic in-
flow and outflow, and bile-duct 
anastomosis for determining the
technically successful living do-
nor liver transplantation (LDLT).
rently.
  Bile duct reconstruction is usually performed last. The 
preferred technique in adult LDLT has been shifted from 
hepaticojejustomy to duct-to-duct anastomosis.
49 Duct-to- 
duct anastomosis can preserve physiologic biloenteric and 
bowel continuity, thus preventing delayed bowel move-
ment, and also allows for endoscopic access to the biliary 
tree for diagnostic and therapeutic instrumentation and 
management and prevent ascending cholangitis.
52
LIVER DONORS
  The principal condition for liver donor is ABO blood 
type compatibility. Histocompatibility is not important for 
liver transplantation as much as kidney transplantation, 
and do not determine whether we do transplant or not. 
Absolute contraindications to organ donation are infec-
tious disease and active malignancy that can cause death 
of the recipient through transmission. Infectious diseases 
include Creutzfeldt-Jakob disease, kuru, Gerstmann-Stru-
ssler-Scheinker syndrome, and fatal insomnia, HIV virus 
infection, disseminated and invasive infection by other vi-
ruses, mycobacterium, or fungi, and systemic infection by 
methicillin-resistant staphylococci. However, low grade 
skin cancer, as basal cell carcinoma, and many squamous 
cell carcinomas, carcinoma in situ (uterine and cervical), 
and primary brain tumors without extracranial metastases 
do not exclude donation.
53,54
1. Donor selection
1) Deceased liver donor
  Selection of an appropriate donor is crucial to the suc-
cessful outcome of DDLT. Among the most prominent 
donor characteristics that may influence the development 
of initial poor function or primary nonfunction in the re-
cipient include old donor age, prolonged ischemia, hypo-
tension and excessive inotropic support, non-heart-beating 
donors and steatosis.
55 Following characteristics described 
an ideal liver donor: 50 years or younger; no hepatobiliary 
disease; hemodynamic and respiratory stability (systolic 
blood pressure ＞100 mmHg, and central venous pressure 
＞5 cm/H2O); an acceptable PaO2 and hemoglobin level; 
n o  s e v e r e  a b d o m i n a l  t r a u m a ,  s y s t e m i c  i n f e c t i o n ,  o r  c a n -
cer; diuresis greater than 50 mL/h and normal creatinine; 
and finally, a dopamine requirement less than 10 μg/ 
kg/min.
56 T h e  c r i t i c a l  s h o r t a g e  o f  d e c e a s e d  d o n o r  g r a f t s  
and the increasing number of recipients awaiting liver 
transplantation make it extremely difficult to limit organ 
selection to the use of ideal donors only. The use of do-
nor with extended criteria for organ acceptance has there-
fore become a necessity in the current era.
57
  Until now, no consensus exists for what an extended 
criteria donor (ECD) graft is, but typically it refers to 
g rafts m ore  com m o n ly  a ssociated  w ith  p oor fu n ction  a n d 
decreased survival on average. This includes older donors, 
donation after cardiac death, grafts from individuals in-
fected with HCV, hepatitis B, steatosis and prolonged 
cold ischemia time.
58,59 Use of ECD increases the pool of 
available donors and reduces the number of deaths on the 
waiting list.
60 In an audit of Organ Procurement and 
Transplantation Network (OPTN) data from over 12,000 
recipients between June 2002 and June 2005, 2,873 grafts 
(24%) were from ECDs. ECD donors are used most com-
monly for the recipients with low MELD scores (＜15)
61 
because the combination of high MELD recipients and 
ECD donors is associated with poor graft function and in-
creased mortality.
58,62 Cameron et al.
62 insisted ECD grafts 
should not be used for critically-ill recipients such as ad-
vanced age and urgent recipients (ALF or ACLF) due to Moon DB, et al: Liver Transplantation   153
Table 3. Worldwide Review on Living Liver Donor Mortality Divided in Early (Postoperative) and Late Mortality
# C-level* Location Donor age/sex/graft Cause of death
Early
1 C1 Hamburg (Germany) 29/f/LS Pulmonary embolism
2 C1 Essen (Germany) 38/m/RL Liver failure in unrecognized congenital lipodystrophy
3 C2 Jena (Germany) 57/f/RL Heart failure, multiorgan system failure: LTx, failed
4 C1 Lyon (France) 32/m/RL Multiple postoperative complication, sepsis
5 C3 Paris (France)  -/-/RL Myeloma, multiorgan failure
6 C3 - (Europe)    - Multiple postoperative complications
7 C2 San Antonio (USA) 23/f/LS Anaphylaxis, anesthesia
8 C1 Chapel Hill (USA) 43/m/RL Sepsis (venous outflow obstruction, bile leak ?)
9 C1 New York (USA) 57/m/RL Aspiration, gas gangrene, Clostridium perfringens
10 C3 California (USA)  -/f/LL Pulmonary embolism
11 C3 - (USA)  -/-/RL Liver failure
12 C1 Curitiba (Brazil) 31/f/RL Cerebral bleeding
13 C3 Recife (Brazil)  -/-/LS Bleeding
14 C3 - (Brazil)  -/-/RL -
15 C3 - (Brazil)  -/-/- -
16 C3 - (Argentina)  -/-/RL Unknown
17 C1 Kyoto (Japan) 46/f/RL Liver failure, nonalcoholic steatohepatitis; LTx, failed
18 C3 - (Korea)  -/-/RL -
19 C3 Suwon City (Korea) 56/m/RL Liver failure, steatosis
20 C1 Hong Kong (China) 50/f/RL Air embolism, duodenocaval fistula, duodenal ulcer
21 C3 Izmir (Trukey) 28/f/RL Pulmonary embolism
22 C1 Singapore 39/m/RL Acute  myocardial  infarction
23 C3 Cairo (Egypt)  -/m/RL Sepsis, bile leak
24 C3 Shinbin El Kom (Egypt)  -/-/RL Liver failure, portal vein thrombosis, bleeding
25 C3 New Dehli (India)  -/-/- Unknown
26 C3 Hyderabad (India) 52/f/- Coma after 48 hours, remained in vegetative state; died
Late
1 C2 Unknown (USA) 35/m/RL Train accident
2 C2 Unknown (USA) 50/m/RL Suicide, gun shot wound; bipolar disorder
3 C1 Philadelphia (USA) 36/f/LS Illicit drug overdose
4 C1 Los Angeles (USA) 35/m/RL Recreational drug overdose, suicide (23 months later)
5 C3 Unknown (Europe)  -/-/- Budd-Chiari syndrome
6 C1 Hamburg (Germany) 30/m/LS Amyotrophic lateral sclerosis (3 years later)
7 C2 Kyoto (Japan) 36/m/LS Unknown (3 years later)
8 C2 - (Japan)  -/m/- Unknown (10 year later)
f, female; m, male; LS, lateral segment; LL, left lobe; RL, right lobe; LTx, liver transplantation.
*Certainty (C) level based on the source of information
C1, Donor death documented, confirmed, and published in the medical literature by an author representing the transplant center 
where the fatality occurred; evidence based on direct information; details of the case often provided, e.g., donor age, sex, graft type, 
date of surgery, cause of death, date of death, survival; C2, Donor death not clearly identified, confirmed or published by transplant 
center where the fatality occurred; transplant center usually not identified; indirect evidence obtained from secondary publications 
by other authors or reviews; eventually some information about the case provided; C3, Donor death not identified, confirmed or 
published; transplant center not identified; evidence based on verbal presentation or personal communication; no further details of 
the case provided. 
Reprinted from Ringe B, Strong RW. The dilemma of living liver donor death: to report or not to report? Transplantation 
2008;85:790-793.
increment of the risk ratio of death by 50%.
2) Living liver donor
  According to Florman et al.
63 report, faced with follow-
ing statistics, death on the waiting list in 2004 was great-
er than 10%, physicians caring for these patients have en-
deavored to perform transplants with partial liver grafts 
from healthy, volunteer liver donors. From this point of 
view, LDLT was an avoidable and inevitable option for 
surgeons to treat end stage liver disease patients in the 
East Asia under extremely rare deceased organ donation 
regardless of ethical issues about donors.
  Organs from living donors offer many potential advan-
t a g e s  o v e r  o r g a n s  f r o m  d e c e a s e d  d o n o r s .  T h e  m o s t  i m -154   Gut and Liver, Vol. 3, No. 3, September 2009
Table 4. Differences between Adult-to-adult LDLT and DDLT
Adult-to-adult LDLT DDLT
Operation
Complex Simple
Recipient’s complication (particularly in bile duct) High Low
Liver graft size Sometimes “Small-for-size” Enough
Liver graft quality Good Sometimes “Poor”
Donor’s complication Morbidity: 16 to 32% Zero
Mortality: 0.4%
Donor’s source Private gift Public resource
LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation.
portant advantages of living donation are that it optimizes 
the timing of transplantation and frees patients from the 
waiting list. Secondly preservation time is minimal, so 
there is significantly less ischemic damage to the liver. 
Therefore, the quality of the donated liver is much better. 
M o s t  i m p o r t a n t l y ,  L D L T  i n c r e a s e s  t h e  g l o b a l  p o o l  o f  
transplantable organs, allowing more people to get trans-
plantation as a life-saving therapy. 
    There are, however, a number of disadvantages to 
LDLT which must be considered carefully. The donor, a 
perfectly healthy volunteer, faces unequivocal risks of 
morbidity and even mortality. To date, more than 12,000 
living donor hepatic resection have been performed wor-
ldwide (ELTR, UNOS, CM Lo, pers. comm., 2006: mor-
tality approaches 0.5% for the right lobe donor in con-
trast to approximately 0.1% for left lobe donation).
64 
Table 3 summarizes the worldwide reported donor’s mor-
talities collected from the international literature and 
from recent reports at professional society meetings.
65 
Additionally, two donors have required liver transplan-
tation for themselves as the result of operative com-
plications.
63
  LDLT also carries certain increased risks for the reci-
pients. It is technically more complex than deceased 
whole liver transplantation. The incidence of biliary com-
plications increased with partial grafts. In addition, the 
small-for-size syndrome is essentially seen only with par-
tial grafts, when the recipient does not receive enough 
functional liver mass. Finally, LDLT procedures are con-
siderably more labor-intensive efforts and prone to result 
in more postoperative complications related to short and 
small hepatic artery, vein, PV and bile ducts (Table 4).
  To be a successful LDLT, appropriate donor evaluation 
is one of the most crucial parts.
66 The goal of evaluation 
process is to exclude donors with an increased risk for 
morbidity and mortality, while at the same time assuring 
that a suitable graft for the recipient can be obtained. The 
person who is willing to be a living liver donor, should 
satisfy the following guiding ethical principles including 
altruism, the absence of coercion or monetary reward, pa-
tient autonomy, beneficence, and nonmaleficence.
67 Addi-
tionally, he is fully informed of the risks and benefits as 
a donor, and fully informed of the risks, benefits, and al-
ternative treatment available to the recipient,
68 because 
d o n o r  s a f e t y  i s  u t m o s t  i m p o r t a n t  is s u e .  T h e r e  c a n  b e  n o 
exceptions to this rule, regardless of the consequences for 
the recipient, even death. 
  Most living donors are in excellent health. Although 
there is no definitive age cutoff, typically ages between 18 
and 55 years are preferred.
65 At our institution, upper age 
limit is 60 years, but biological age is more important 
than donor’s chronologic age. However, careful caution is 
necessary for older age donor (＞50 years) who is asso-
ciated with a fourfold risk of complications.
69 Lower age 
limit can be lowered to 16 years only when the recipient 
is the donor’s parent.
19
  Fatty liver is dangerous for both donor and recipient. 
The Vancouver Forum participants
64 suggested that donor 
liver biopsy should be performed if blood specimen liver 
tests are abnormal and if steatosis or other abnormalities 
are noted on imaging studies. Additionally, the histo-
logical findings that should preclude living liver donation 
were also clearly defined during Forum. They include (i) 
portal or sinusoidal fibrosis, (ii) nonalcoholic steatohepa-
titis, (iii) steatosis ＞20% (only for right liver), and (iv) 
portal inflammation or necroinflammatory changes.
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Fig. 9. Split liver transplanta-
tion to two adult recipients in 
order to expand the donor pool 
at Asan Medical Center. This is 
the first time that this pro-
cedure was performed in Korea, 
in August 2003.
biopsy could unveil unexpected liver pathology (as high 
as 21%),
65 and body mass index is an inaccurate indicator 
of steatosis, so many centers advocate routine liver biopsy 
in the donor evaluation protocol.
70 In our experience, rou-
tine application of preoperative donor liver biopsy make 
us avoid invalid donor operation,
19 and biopsy related do-
nor complication has been minimized with help of the 
hands of experienced practitioner coupled with careful 
post-biopsy observation. If the transplant is not urgent, 
we recommend the potential donor with liver steatosis to 
reduce body weight and to perform vigorous exercise. 
Successful reduction of liver steatosis is possible and don-
ation is acceptable.
71
  Regarding to ABO blood type in LDLT, identical or 
compatible ABO blood type between recipient and donor 
is recommended; however, ABO incompatible blood type 
LDLT has been undertaken successfully in special in-
stance such as infant ＜1 year of age without presence of 
isoagglutinins, and in emergency situations where no de-
ceased donor allograft is available.
72 Recently, the group 
of Kyoto,
73 Chicago,
74 and Gent
75 demonstrated the feasi-
bility of adult  LDLT across ABO barriers by using differ-
ent approaches and immunosuppressive protocols. At our 
institution, the liver donor-exchange program for adult, as 
in kidney transplantation, has performed to overcome 
blood group mismatching in 5 donor-recipient pairs since 
2003, and also started ABO incompatible adult-to-adult 
LDLT successfully in 2008.
19
  By definition, a living donor is a completely healthy 
person. It is the consensus that potential donors with 
concomitant medical illness should not be allowed to 
donate.
70 However, the presence of mild systemic disease, 
such as well controlled mild hypertension or diet-con-
trolled diabetes, is not necessarily a contraindication to 
donation.
76
  Extensive blood tests are considered necessary to detect 
HIV, HCV, or hepatitis B virus (HBV) infection, and lab-
oratory testing for a preexisting hypercoagulable condition 
especially if the potential donor has a history of venous 
thrombosis.
64,77 The HBcAb positive donor can donate for 
a recipient affected by HBV-cirrhosis and HBV naïve re-
cipient also with prophylaxis of hepatitis B immuno-
globulin.
19
  Imaging study of the liver is needed to exclude paren-
chymal liver disease, to identify the vascular and biliary 
anatomy and to estimate the graft and remnant liver 
volume. As a ‘all in one’ procedures to simplify and 
shorten such time-consuming and costly procedure, use of 
multidetector CT is helpful to evaluate them in a single 
diagnostic study,
78,79 and is better than magnetic reso-
nance imaging in the ability to accurately assess the bili-
ary anatomy.
78 It is generally believed that a remnant liver 
of at least 30% of the original liver volume with complete 
venous drainage is safe for donor survival and a graft that 
provides 40% of the estimated standard liver volume
80 or 
0.8% of the body weight of the recipient is necessary for 
the recipient recovery.
19,64,81 Volumetric imaging analysis 
m a y  o v e r e s t i m a t e  t h e  a c t u a l  l i v e r  v o l u m e  b y  a s  m u c h  a s 
10%. The main cause of the overestimation is related to 
the difference between the vital liver filled with blood in 
vivo and the graft that is in a state of collapse ex vivo.
2. Donor procurement
1) Deceased liver donor
    Whole organ procurement is now a well described 156   Gut and Liver, Vol. 3, No. 3, September 2009
Fig. 11. Most commonly used 
graft for adult-to-adult LDLT. 
(A) Right lobe graft, (B) Left 
lobe graft.
Fig. 10. Segmental anatomy of the liver using the Couinaud’s
segments. Reprinted from Brown RS Jr. Live donors in liver 
transplantation. Gastroenterology 2008;134:1802-1813.
procedure. The principles of minimum mobilization to de-
fine vascular structures, in situ perfusion with 4
oC preser-
vation solution, and sequential en bloc harvest of organs 
yield good allograft preservation. 
  “Split liver” grafting involves the preparation of two al-
lografts from a single donor.
82 In most cases, the ex-
tended right lobe allograft (segment 4-8) is used in an 
adult or large child, while the left lateral segment allog-
raft (segment 2,3) is transplanted into a small recipient. 
At our institution, split liver transplantation for two adult 
recipients has been performed successfully to more than 
16 adult recipients.
83 The whole liver is divided into right 
lobe without middle hepatic vein (MHV), same to modi-
fied right lobe graft in LDLT, and left liver with IVC and 
common hepatic artery by using in situ or ex vivo techni-
que (Fig. 9).
2) Living liver donor
  The performance of LDLT relies on an understanding of 
the vascular and biliary anatomy of the liver. The left 
hepatic lobe consists of left lateral sector (Counaud seg-
ment 2 and 3) and medial sector (Counaud segment 4); 
and Counaud segment 5,6,7 and 8 compose the right 
hepatic lobe (Fig. 10). Counaud segment 1 is the caudate 
lobe. For most people the left lateral sector comprise 
20% of their total liver volume, the left lobe 40%, and 
the right lobe 60%. In general, the common grafts that 
can be used from a living donor for transplantation in-
clude the left lateral sector, the left lobe (with or without 
caudate lobe), and the right lobe (Fig. 11).
  The argument for the need of including the MHV in 
right lobe graft continues ever since its inception. Hong 
Kong group advocates for right lobe with MHV. They be-
l i e v e  t h a t  M H V  i s  t h e  i m p o r t a n t  d r a i n a g e  v e i n  o f  s e g -
ments 5 and 8, and sometimes 6.
84,85 Right lobe graft 
without MHV will lead to graft congestion, drainage of 
hepatic artery blood via the right anterior portal vein, 
persistence of portal hypertension, and excessive blood 
flow into the right posterior sector leading to serious 
graft damage. However, the most important shortcoming 
of this liver graft is hampering the donor safety (Fig. 12). 
Actually graft type of the donor deaths after liver dona-
tion from Hong Kong, Japan, and Korea were all right 
lobe with MHV grafts.
65 In addition, the majority of pro-
grams in the United States shows that this is too large a 
liver resection for a healthy donor, who does not essen-
tially require surgery, and increase the risk of small-for- 
size syndrome and the subsequent postoperative liver fail-
ure in the donor.
76 Marcos et al. advocates for right lobe 
without MHV, because donor safety could be ensured, in-
trahepatic venous collaterals are present in between the 
middle and right hepatic vein branches,
86 and the in-
cidence of graft congestion is very low. However, collater-
als between the right hepatic vein and MHV are small 
and late in development and are not present in every Moon DB, et al: Liver Transplantation   157
Fig. 12. Congestion of the me-
dial sector after procurement of 
the right lobe with a middle 
hepatic vein graft from a living 
liver donor. (A) Preoperative 
CT scan showing the donor 
liver and imaginary parenchy-
mal transection line when the 
right lobe with the middle 
hepatic vein graft is harvested. 
( B )  C T  s c a n  m a d e  o n  t h e  7 t h  
postoperative day, revealing a 
large area of congestion at the 
medial sector.
Fig. 13. A scheme for modified 
right lobe (MRL) liver grafting. 
RHV, right hepatic vein; MHV, 
middle hepatic vein; LHV, left 
hepatic vein; V5, hepatic ven-
ous tributaries from segment 5; 
V8, hepatic venous tributaries 
from segment 8.
case.
87 Lee et al. noted world first about the importance 
of congestion and its drainage in the anterior sector of 
right lobe graft without MHV,
87 and initiated modified 
right lobe graft, which is right lobe graft without MHV 
but restoring the continuity of sizable segment 5 and 8 
(≥5 mm) venous drainage in the graft by using venous 
conduit (Fig. 13).
17,88 After clinical application of this 
graft type, 6-months recipient survival rate improved from 
71% to more than 90% at our institution.
89 In some rare 
instance, right posterior sector (Counaud segment 6,7),
90 
and monosegment graft have been used.
91
  During recipient and donor workup for adult LDLT, 
heartbreaking cases who can not be transplanted from a 
single donor due to graft-recipient size mismatching, un-
acceptable right-to-left lobe volume discrepancy and ex-
cessive hepatic steatosis, are not uncommon. Under those 
circumstance, Lee et al. has performed dual-graft adult 
LDLT in which two left liver (left lateral sector or left 
lobe) grafts are procured from two donors and implanted 
in one recipient, in order to achieve maximal donor safety 
through minimal resection of liver mass while increasing 
recipient actual graft volume (Fig. 14).
19,92,93 Sometimes 
right lobe or right posterior sector graft also has been 
used for right-sided liver graft of dual-graft LDLT because 158   Gut and Liver, Vol. 3, No. 3, September 2009
Fig. 14. Postoperative follow-up CT scan of the recipient, 
demonstrating the balanced regeneration of both liver grafts. 
(A) CT scan taken 5 days after transplantation showing that 
the second left lobe graft in the right upper abdomen was still
small and supported by a tissue expander bag. (B) CT scan 
made 2 weeks after transplantation, showing the rapid 
regeneration of both grafts. (C) CT scan made 2 months after 
transplantation, showing that two regenerated left lobe grafts 
were in the shape of a normal liver.
of the recipient body size or anatomic variation of donor 
liver (Fig. 15). At our institution, various types of single 
liver graft together with dual-grafts has been used to sat-
isfy both donor safety and recipient metabolic demands 
(Fig. 16).
  As an incision line for all types of donor hepatectomy, 
a right subcostal incision with midline extension is ad-
equate and spares the donor morbidity of dividing the 
rectus muscle bilaterally.
63 In addition to conventional 
open techniques, Cheriqui et al.
94 reported for the first 
time laparoscopic left lateral sector retrievals for pediatric 
LDLT. Recently at our institution also, laparoscopic left 
lateral sector donor hepatectomy has been performed rou-
tinely for pediatric LDLT. Intraoperative cholangiography 
by using a radio-opaque marker tagging method and di-
rect bile duct probing through the cystic duct was rou-
tinely used to identify an adequate location for bile duct 
division, minimizing the number of graft duct openings 
obtained from various donor bile duct anatomies.
95 For 
the parenchymal transection, ultrasound or water-jet dis-
sector are generally used in combination with electro-
cautery under without hilar occlusion or using only inter-
mittent clamping.
96 Graft retrieval is performed without 
portal cannulation in donor’s abdominal cavity. Pinching 
of the portal vein wall with the cannula in situ or pushing 
the tube into the right anterior or posterior PV is effi-
cient for uniform flushing of the liver graft. The need for 
hepatic artery flushing by preservation flushing is 
controversial. Finally, in case of modified right lobe graft, 
vascular conduits using recipient’s great saphenous vein, 
PV, umbilical vein, or cryopreserved cadaveric vessels are 
employed to establish the good outflow of the graft.
88,97,98 
In case of right lobe with MHV, Hong Kong group pre-
ferred to perform venoplasty of the right hepatic vein/ 
MHV to form a large triangular orifice.
99 At our center, 
however, quilt venoplasty using recipient’s graft saphe-
nous vein and cryopreserved vessels is used to make a 
large single orifice.
100 Before wound closure, the left liver 
remnant should be anchored to the anterior abdominal 
wall to prevent its rotation into the right subphrenic cav-
ity and subsequent outflow obstruction.
101
IMMUNOSUPPERSSION AFTER LIVER TRANS-
PLANTATION
  After introduction of cyclosporine, a number of new 
immunosuppressants (tacrolimus, mycophenolate mofetil, 
sirolimus, interleukin-2 receptor blocker, humanized mon-
oclonal antibody, etc) are available currently. Large series 
describing results from the previous years mention acute 
rejection in 40 to 60% of liver transplant patients.
102,103 Moon DB, et al: Liver Transplantation   159
Fig. 15. Two hundred and fifty- 
eight dual-graft adult-to-adult 
LDLTs were performed between 
March 2000 and December 2008
at the Asan Medical Center. 
*Two recipients received a left 
lobe from a live donor and a 
split lateral segment from a 
deceased donor, respectively, on 
June 2000 and December 2008, 
respectively; 
†
Right lobe (from 
wife) and left lobe (from co-
usin) dual-graft adult-to-adult 
LDLT for a large-size recipient 
was performed successfully in 
April 2001. Lateral section 
replaced the left lobe in 10 of 
47 recipients.
Fig. 16. Types of graft in 1,739 
adult-to-adult LDLTs. 
MRL, modified right lobe; RL, 
right lobe; LL, left lobe; S1, 
caudate lobe; ERL, extended ri-
ght lobe; RPS, right posterior 
sector; E-LLS, extended left la-
teral segment.
More recent data from USA for 2003 show acute rejection 
in as few as 18% of patients (www.unos.org). Vast ma-
jority of patients can be treated satisfactorily with boluses 
of steroids. Chronic rejection is a rare event in liver 
transplantation, occurring in less than 5% of patients.
104
  In the majority of liver transplant recipients, combina-
tion of two or three different maintenance immunosu-
ppressive drugs is used for prevention of rejection. The 
calcineurin inhibitors tacrolimus and cyclosporine are the 
mainstays of immunosuppression in liver transplantation. 
Over 95% of patients are discharged with a calcineurin 
inhibitor as a primary immunosuppressant, with tacroli-
mus being most frequently used (www.unos.org). 
    Steroids are still almost universally used after liver 
transplantation. Most patients are discharged with ste-
roids, which are subsequently tapered and weaned in the 
following months. 
  Mycophenolate mofetil (MMF), which is antimetabolites 
such as azathioprine, is also frequently used to reduce 
calcineurin inhibitor dose and to prevent or limit side ef-
fects such as renal dysfunction, hypertension and hyper-
lipidemia. UNOS data show that 60% of patients are dis-
charged from the hospital on the use of MMF, same in 
our institute.
    Sirolimus (Rapamycin) is a new immunosuppressive 
agent, which is structurally similar to tacrolimus, and has 
antifibrotic and antineoplastic characteristics, but lack of 
nephrotoxicity. However, severe side effects, including de-
layed wound healing and vascular complications limit its 
clinical usage.
105 In general one can say that currently the 
most important challenge with regards to immunosu-
ppression in liver transplantation is not to find drugs that 
are more powerful, but drugs that are less harmful. In the 
mean time, the present availability of a wide spectrum of 
effective and specific immunosuppressive drugs allows in-
dividualized selection of drugs, thereby limiting serious 160   Gut and Liver, Vol. 3, No. 3, September 2009
Table 5. Allograft Dysfunction and Surgical Complications 
Occurring in the Immediate Postoperative Period 
Allograft dysfunction
  Primary non-function
  Primary poor function 
  Acute cellular rejection
  Recurrent viral hepatitis
  Drug hepatotoxicity
Surgical complications
  Postoperative hemorrhage
  Vascular complications 
    Hepatic artery thrombosis
    Portal vein stenosis or obstruction
    H e p a t i c  v e i n  s t e n o s i s  o r  o b s t r u c t i o n
    O t h e r
  Biliary tract complications
    B i l e  l e a k  o r  f i s t u l a
    B i l i a r y  s t r i c t u r e
side effects.
25
COMPLICATIONS
1. Early post-transplant complications
  Postoperative technical and organic medical complica-
tions, primary dysfunction, graft rejection and infections 
are the major short-term complications (Table 5).
106
  During the initial 48-72 postoperative hours, abnormal 
liver biochemistries are typical and reflect a number of in-
sults to the graft, including following harvesting, preser-
vation, and subsequent reperfusion. However, daily rou-
tine Doppler ultrasound exam should be performed to ex-
clude vascular complications such as hepatic artery thro-
mbosis, portal and hepatic vein stenosis or obstruction. 
  Biliary complications are considered the Achilles’ heel 
of LT, particularly in the setting of LDLT. The rate of bile 
leak or stricture at the anastomotic site or cut edge of the 
transected liver, were reported in 15-60% of recipients in 
early, single center reports.
76 At our institution, cumu-
lative biliary complication rate after LDLT rose to 20.2% 
in 5 years, and most stenosis was successfully treated us-
ing radiologic intervention.
107
  Within the first week after LT, liver biochemistry stead-
ily improve as ischemia and reperfusion damage resolves, 
and also the volume of transplanted liver graft is regen-
erating. Acute rejection becomes an important and fre-
quent cause of graft dysfunction at 1 week and beyond. 
Liver biopsy is necessary for confirmatory diagnosis.
  Various infectious complications following liver trans-
plantation can occur, and opportunistic infections related 
to intensive immunosuppresion are relatively common 
such as cytomegalovirus, Pneumocystis carinii, and fungal 
infection.
    Neurologic dysfunction, hyperglycemia and renal im-
pairment can occur mainly related to the toxic effects of 
cyclosporine and tacrolimus. 
2. Long-term complications
  Today, with improved survival in most transplant cen-
ters, increasing attention is being given to complications 
that develop in the long-term, and that are highly related 
to the immunosuppressive treatment. The most frequent 
complications are chronic renal failure, hypertension, dia-
betes mellitus, dyslipidemia, obesity, bone or neurological 
complications, development of de novo tumors.
108
  Impaired renal dysfunction before transplantation, chro-
nic use of calcineurin inhibitors and hypertension prob-
ably all contribute to the increased risk for chronic renal 
failure after liver transplantation. The cumulative risk of 
renal failure has been described to be as high as 20% five 
years after transplantation.
109 Strenuous management of 
hypertension and withdrawal or reduction of calcineurin 
inhibitors in an early stage should be considered. 
    Hypertension, diabetes, hyperlipidemia, and obesity, 
which are well-known risk factors for cardiovascular dis-
ease, occur in up to 75%, 15%, 40-60%, and 30-70% of 
patients, respectively, long-term after transplantation.
110,111 
This increase in risk factors is at least partly due to con-
tinuous immunosuppressive drugs. This combined with 
high risk behavior leads to a markedly increased risk for 
arthrosclerosis and subsequent cardiovascular events.
112 
Vigorous screening for cardiovascular risk factors and ag-
gressive management is essential for all liver transplant 
recipients. 
  Increased risk for osteoporosis in liver transplant recipi-
ent results from the combination of low bone mineral 
density before transplantation due to hepatic osteodys-
trophy, malnutrition and inactivity and steroid use after 
transplantation.
112 In the present era, with lower dosages 
of corticosteroids and the availability of bisphosphonates, 
bone disease can be prevented and treated easier than the 
earlier era. 
  Varying degree of neurological complications develop in 
large proportion of liver transplant recipient mostly sec-
ondary to calcineurin inhibitor. Tremor is the most com-
mon symptom, and headache, paresthesia, or insomnia is 
other complaints that can be actually very disabling. 
Reduction of immunosuppressive drug dose might be 
helpful. 
  De novo malignancy has an incidence of 5-16% in dif-
ferent series.
113 I t  i s  a  m a j o r  c a u s e  o f  l a t e  d e a t h  i n  l i v e r 
transplant recipients.
114 There is irrefutable evidence of an 
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after liver transplantation.
115 The incidence of orophar-
yngeal, esophageal, lung, throat, and tongue cancer may 
also be increased.
116 The contributors to this increased 
risk are high-risk behavior before transplantation (smo-
king, alcoholism) and the life-long use of immunosup-
pressive drugs. Consequently, post-transplant manage-
ment should focus on the elimination of risk factors, as 
well as minimizing the amount of immunosuppression. 
RECURRENT DISEASE AFTER TRANSPLANTA-
TION
  In the early 1990s hepatitis B recurrence was observed 
more than 80% of liver transplant recipients. Currently, 
effective antiviral prophylaxis with high dose hepatitis B 
immunoglobulin has virtually eliminated HBV recurre-
nce.
117 Overall survival of patients transplanted for HBV- 
related cirrhosis currently exceeds 90% at one year and 
85% at 5 years.
23
  Recurrence of hepatitis C is almost universally seen. It 
usually presents gradually in the postoperative courses, 
but accelerated compared to the pretransplant setting. 
Protocol biopsies done 5 years after transplant showed 
that 20% of patients transplanted for HCV already had 
evidence of allograft cirrhosis.
118 During recent years, 
h o w e v e r ,  i m p r o v e d  s u r v i v a l  o f  p a t i e n t s  t r a n s p l a n t e d  f o r  
HCV has been seen, with a 10-year patient survival of ap-
proximately 60%.
119 Recent study using combination of 
ribavirin and pegylated interferon for recurrent HCV pa-
tients after LT showed some promising preliminary re-
sults.
120
  Recurrence of HCC is especially common in patients 
with a poorly differentiated tumor or macroscopic vas-
cular invasion.
120 Various treatment including surgical re-
section, transarterial chmoembolization, radiofrequency 
ablation, chemotherapy, and radiotherapy, should be per-
formed for recurrent HCC. The outcome is universally 
dismal, but long-term survival is possible in a few se-
lected cases received radical treatment.
121
  Recurrence of autoimmune disease in an organ from a 
donor is immunologically intriguing. Diagnosis can be dif-
ficult due to other potential causes for graft dysfunction. 
Recurrence of an early stage of primary biliary cirrhosis 
may occur in a majority of patients transplanted for this 
indication in the long term, but seldom leads to cir-
rhosis.
122
  Recurrence of autoimmune hepatitis is seen in 22% of 
patients, and is treated as in nontransplant patients.
123 
Recurrence of primary sclerosing cholangitis occurs in 
about 11% of patients,
123 diagnosis may be difficult be-
cause of overlap with nonanastomotic strictures from oth-
er causes. 
  Retransplantation for recurrent disease is a difficult eth-
ical issue faced by transplant teams in an era of intract-
able organ shortage. Perioperative risk, survival, quality of 
life, as well as the presence of comorbidities such as renal 
failure related to immunosuppression toxicity all need to 
be weighed in the decision to retransplant.
43
RECIPIENT OUTCOMES
  The survival rates after DDLT are expected more than 
85% and 75% at 1-year and 5-years post-transplantation, 
respectively.
124 The survival rate after LDLT was much 
l o w e r  t h a n  D D L T  a t  t h e  t i m e  o f  b e g i n n i n g .  H o w e v e r ,  
L D L T  h a s  e v o l v e d  t o  b e  a  v a l u a b l e  s t r a t e g y  i n  r e d u c i n g  
waiting list mortality for pediatric patients and adult pa-
tients with chronic liver disease, ALF and HCC. In the 
E a s t  A s i a  i n c l u d i n g  K o r e a ,  J a p a n ,  H o n g  K o n g ,  w h e r e  d e-
ceased organ donation is very rare, marked improvement 
of graft survival around 85% had achieved with help of 
accumulation of knowledge about portal inflow modu-
lation, adequate graft size and venous outflow drainage, 
and technical innovations in LDLT during early period of 
2000s.
17,125,126 A recent retrospective analysis of the Adult- 
to-Adult LDLT cohort study (A2ALL) group clearly sho-
wed, that graft failure rate correlated with experience; i.e., 
centers with more than 20 LDLT had a significantly lower 
graft failure risk.
126 Accordingly, more recent studies re-
ported similar patient survival rates among living donor 
and deceased donor liver transplant recipient.
61,127,128 
A2ALL consortium and from UNOS data base, however, 
showed that LDLT was not the most appropriate solution 
for the patients with a MELD score ＞30, so-called, ACLF 
or chronic liver disease with severe decompensation,
129,130 
because the post-transplantation survival rates are poor 
(57%), compared to 82% survival rate in deceased donor 
liver transplant recipients who were on same sever-
ity.
131,132 Recently patient survival rate after adult LDLT at 
our institution is 90.7% and 85.2% at 2-year and 5-years 
post-transplantation,
19 and A2ALL’s recommendation for 
ACLF patients is invalid because our large LDLT series 
showed 84% and 79% survival rate for high MELD (＞
30) recipients at 1-year and 5-years post-transplantation,
47 
comparable results to DDLT.
131 It could be only possible 
with the technical refinement by transplant surgeons and 
the 24 hours intensive postoperative care by dedicating 
young surgeons, because postoperative courses of LDLT 
using partial liver graft is a dynamic process necessitating 
rapid graft regeneration and it can cause unpredictable 
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CONCLUSIONS
    Liver transplantation has revolutionized the manage-
ment of acute and chronic liver diseases. The scarcity of 
donor organ is still the factors limiting its use. Expansion 
of the donor pool with increasing use of extended criteria 
organs has increased greatly over the last few decades. In 
the East Asia, LDLT has been a good alternative to DDLT 
regardless of disease severity and currently the outcome 
is not different between them. With improved survival in 
most transplant centers, increased attention should be 
given to complications that develop in the long-term.
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